Correspondence 0001193125-26-074564 from enGene Therapeutics Inc. (ENGN)
enGene Therapeutics Inc.
Date: Feb. 26, 2026 · CIK: 0001980845 · Accession: 0001193125-26-074564
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293597
Letter
enGene Holdings Inc. 4868 Rue Levy, Suite 220 Saint-Laurent, QC H4R2P1 (514) 332-4888 February 26, 2026 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Jimmy McNamara Re: enGene Holdings Inc. Registration Statement on Form S-3 Filed February 19, 2026 File No. 333-293597 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, enGene Holdings Inc. hereby requests acceleration of the effective date of the above-referenced registration statement on Form S-3, so that such registration statement may become effective at 4:00 P.M. (Washington, D.C. time) on March 2, 2026, or as soon as practicable thereafter. The Registrant hereby authorizes David Bionghi, of Morgan, Lewis & Bockius LLP to orally modify or withdraw this request for acceleration. Please contact David Bionghi of Morgan, Lewis & Bockius LLP at +1.212.309.6138 or david.bionghi@morganlewis.com with any questions you may have concerning this request, and please notify him when this request for acceleration has been granted. enGene Holdings Inc. By: /s/ Ronald H.W. Cooper Name: Ronald H.W. Cooper Title: Chief Executive Officer
Show Raw Text
CORRESP 1 filename1.htm CORRESP enGene Holdings Inc. 4868 Rue Levy, Suite 220 Saint-Laurent, QC H4R2P1 (514) 332-4888 February 26, 2026 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Jimmy McNamara Re: enGene Holdings Inc. Registration Statement on Form S-3 Filed February 19, 2026 File No. 333-293597 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, enGene Holdings Inc. hereby requests acceleration of the effective date of the above-referenced registration statement on Form S-3, so that such registration statement may become effective at 4:00 P.M. (Washington, D.C. time) on March 2, 2026, or as soon as practicable thereafter. The Registrant hereby authorizes David Bionghi, of Morgan, Lewis & Bockius LLP to orally modify or withdraw this request for acceleration. Please contact David Bionghi of Morgan, Lewis & Bockius LLP at +1.212.309.6138 or david.bionghi@morganlewis.com with any questions you may have concerning this request, and please notify him when this request for acceleration has been granted. enGene Holdings Inc. By: /s/ Ronald H.W. Cooper Name: Ronald H.W. Cooper Title: Chief Executive Officer